Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
"Novartis, Clinician",Secukinumab,"Ankylosing spondylitis, 1st biologic line",Secukinumab,Recommended for decline,Community and Hospital,Musculoskeletal System
